A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer

192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC

(2016) T. Mok et al.   Journal of Thoracic Oncology

191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC

(2016) S. Peters et al.   Journal of Thoracic Oncology

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology

(2015) Meagan S. Barbee et al.   ANNALS OF PHARMACOTHERAPY

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade

(2015) Elizabeth Buchbinder et al.   JOURNAL OF CLINICAL INVESTIGATION

Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab

(2014) Gary Hunter et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Myosite orbitaire associée à un traitement par ipilimumab

(2013) M. Lecouflet et al.   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY